Skip to content

Climb Bio, Inc. CLYM Short-Term Investments

Short-Term Investments at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$912M+0.6%
Vera Therapeutics logo
Vera TherapeuticsVERA
$482.41M-9.8%
Kyverna Therapeutics, Inc. logo
Kyverna Therapeutics, Inc.KYTX
$204.25M+9.9%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
$276.8M+21.8%
Jade Biosciences, Inc. Common Stock logo
Jade Biosciences, Inc. Common StockJBIO
$256.21M+701%
Artiva Biotherapeutics, Inc. logo
Artiva Biotherapeutics, Inc.ARTV
$65.83M-51.4%

Other financials

Income statement

See full
Operating income-$15.2M+33.9%
Net income-$13.7M+34.0%
EPS (diluted)-$0.20+35.5%

Balance sheet

See full
Cash & equivalents$8.4M-71.2%
Total debt$479.0K+1.1%
Total equity$148.1M-23.4%
Total assets$152.4M-24.1%

Cash flow

See full
Operating cash flow-$14.4M+6.8%
CapEx$109.0K
Free cash flow-$15.6M-183%

Valuation

See full
Market cap$724.95M+787%
Enterprise value$717.07M+1,247%

Returns & leverage

See full
Return on equity-30.9%-10.3pp
Debt / equity0.0×
Current ratio27.9×+13.6×

Where this comes from

Reported directly by Climb Bio, Inc. in its filing.

Tagged under the XBRL concept us-gaap:MarketableSecuritiesCurrent.

The official record: Climb Bio, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Climb Bio, Inc.'s short-term investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Climb Bio, Inc.'s short-term investments?
Climb Bio, Inc. (CLYM) reported short-term investments of $101.21M in Q1 2026.
How has Climb Bio, Inc.'s short-term investments changed year-over-year?
Climb Bio, Inc.'s short-term investments increased by 46.6% year-over-year, from $69.04M to $101.21M.
What does short-term investments mean?
Marketable securities and other investments with maturities between three months and one year, providing yield above cash while maintaining liquidity.